Genevant Sciences Gmbh

Ceptyr, Inc.

Myriad Genetics, Inc.

Phaserx, Inc.

Maher Qabar

Mary Gallagher Prieve

Charbel Diab

Pierrot Harvie

Sean D Monahan

Anna Galperin

Michael S DeClue

Debashish Roy

Amber E Paschal

Russell N Johnson

Thomas Little

Michael E Houston, Jr

Jennifer Lynn Gage

William C Patt

Mark Arnold Thomas Blaskovich

Gangadhar Nagula

Ted Baughman

James Jeffry Howbert

Michael S Declue

Mary G Prieve

Feng Hong

Danwen Huang

Marcin Stasiak

Jessymol Mathew

Michael E Houston

Lauri Mario Schultz

Lauri Marie Schultz

Jr Houston Michael E

Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.

Block copolymers

Nucleic acid constructs and methods of using the same

The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases. 

Protein tyrosine phosphatase inhibitors and methods of use thereof

Reverse-turn mimetics and methods relating to the same having the following structure are disclosed: including pharmaceutically acceptable salts and stereoisomers thereof, wherein R, R, Rand Rare as defined herein. Such compounds have utility over a wide range of applications, including use as diagnostic and therapeutic agents. In particular, compounds of this invention, and pharmaceutical compositions containing such compounds, are neurokinin (tachykinin) antagonists. Libraries containing the reverse-turn mimetics of this invention are also disclosed.

Reverse-turn mimetics and compositions and methods relating thereto

Growing community of inventors

Sammamish, WA, United States of America

Maher Qabar